[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100235711":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":17,"centralContacts":24,"locations":32,"responsibleParty":55,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":75,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8,11,14],{"label":9,"type":10,"description":10,"interventionNames":10},"Active Surveillance",null,{"label":12,"type":10,"description":13,"interventionNames":10},"Immediate Intervention","May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.",{"label":15,"type":10,"description":16,"interventionNames":10},"Crossover (Delayed Intervention)","Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.",[18,22],{"name":19,"affiliation":20,"role":21},"Mohamad E Allaf, MD, MBA","Johns Hopkins University","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":20,"role":21},"Nirmish Singla",[25,29],{"name":23,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","410-502-3692","nsingla2@jhmi.edu",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":31},"Tina Driscoll","twlajni1@jhmi.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Johns Hopkins Hospital","RECRUITING","Baltimore","Maryland","21287","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-76.61219,39.29038,{"lat":45,"lon":44},[48,52,54],{"name":49,"role":26,"phone":50,"phoneExt":10,"email":51},"Phillip M Pierorazio, MD","4105025984","philpierorazio@jhmi.edu",{"name":49,"role":53,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":19,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[58],{"name":59,"class":60},"National Comprehensive Cancer Network","NETWORK","100235711","the-delayed-intervention-and-surveillance-for-small-renal-masses-dissrm-registry-100235711",false,"NCT02346435","The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry","DISSRM","Inclusion Criteria:\n\n* Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.\n* Age ≥ 18 and able to read, understand and sign informed consent.\n* Must be willing to adhere to the treatment algorithm and time constraints therein.\n\nExclusion Criteria:\n\n* Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.",true,"ALL","18 Years","100 Years",{"count":73,"type":74},600,"ESTIMATED","5 Years","OBSERVATIONAL","Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \\\u003C=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.",[79],"Kidney Neoplasm",[81,82],"small renal mass","active surveillance","2026-03-04",{"date":85,"type":86},"2026-03-05","ACTUAL",{"date":88,"type":10},"2009-01",{"date":90,"type":74},"2028-01",{"name":5,"class":6},1]